Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 12/20 | 0.58 |
| ▸ | NPC1 | O15118 | 11/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | ACP1 | P24666 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2793209 | 0.88 | DYRK1A (0.65) | DYRK1ARAB9ANPC1SMN1; SMN2TP53 | |
| Potassium Ion SCHEMBL2790230 | 0.85 | DYRK1A (0.61) | DYRK1ARAB9ANPC1SMN1; SMN2PTPN1 | |
| Potassium Ion SCHEMBL2791883 | 0.85 | ABL1 (0.48) | DYRK1ARAB9ANPC1SMN1; SMN2ACP1 | |
| Potassium Ion SCHEMBL2790234 | 0.85 | ABL1 (0.66) | DYRK1ARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL14189671 | 0.85 | ABL1 (0.70) | DYRK1ARAB9ANPC1SMN1; SMN2TP53 | |
| Potassium Ion SCHEMBL2791076 | 0.82 | NPC1 (0.69) | DYRK1ARAB9ANPC1SMN1; SMN2ACP1 | |
| SCHEMBL23328883 | 0.81 | ACP1 (0.70) | DYRK1ARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL5019481 | 0.80 | DYRK1A (0.74) | DYRK1ARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2175580 | 0.77 | DYRK1A (1.00) | DYRK1ARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL19844513 | 0.77 | RAB9A (0.70) | DYRK1ARAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012481-B2 | Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-04-21 | — | — | US | disclosed |
| US-20110319456-A1 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-12-29 | — | — | US | disclosed |
| WO-2010077068-A2 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319456-A1 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | HTT, PSEN1, PYGB | DYRK1A 3176/4885RAB9A 3642/4885NPC1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.